

EMUNO Therapeutics Achieves Research Milestone with Enamine's IDD Platform

Enamine's Target-Agnostic Expertise in Biology, Drug Design, and Medicinal Chemistry Advances EMUNO Therapeutics Pipeline

KYIV, UKRAINE, January 22, 2026

[/EINPresswire.com/](https://EINPresswire.com/) -- EMUNO

Therapeutics reached critical R&D milestones with remarkable efficiency in their fight against cancer supported by the competence and Integrated Drug Discovery (IDD) Platform of the CRO Enamine. EMUNO and Enamine entered a comprehensive collaboration in June 2025 to advance EMUNO's small molecule programs in immunology aimed at achieving clinical impact for challenging malignancies.

EMUNO's mission is to develop medicines which modulate specific immune responses in a controlled, pathway-specific approach to treat autoimmune disorders or overcome cancer immune evasion, and to enhance human health and wellbeing. The European Union supports their small molecule immune activator program with an EIC Transition Grant from the European Innovation Council. The IMMUNOCON project aims to advance the drug candidate EMT-224 towards clinical readiness to address the urgent need for effective therapies



EMUNO
THERAPEUTICS

European
Innovation
Council



Co-funded by
the European Union

for refractory and treatment-resistant solid tumors, commonly seen in advanced/ late-stage cancer patients.

Enamine's agile IDD Platform of Computer-aided Drug Design (CADD), together with AI/ML approaches, innovative medicinal chemistry, and preclinical biology, including its capabilities in guiding structure-based drug design, fragment-based approaches as Enamine UFrag™, and Enamine's source of drug-relevant chemical space through the REAL compounds, enabled very short and effective design-make-test-analyze cycles across its research infrastructure.

Enamine's profound knowledge of chemical space, namely with its REAL compounds, is the world's largest collection of make-on-demand small molecules that represents a significant fraction of such synthetically accessible chemical space. Its member molecules are REadily AccessibLe through validated parallel synthesis protocols using qualified in-stock building blocks.

Enamine Germany in Frankfurt enables support of rapid lead optimization and project management. Enamine's capabilities in biology, from hit identification, lead optimization, and translating into preclinical proof-of-concept studies, are critically supported by its biology research centers in Kyiv and Wroclaw through their high-throughput screening, ADME , and PK/Tox , and other biological capabilities.

Enamine's agile IDD Platform of Computer-aided Drug Design (CADD), together with AI/ML approaches, innovative medicinal chemistry, and preclinical biology, including its capabilities in guiding structure-based drug design, fragment-based approaches as Enamine UFrag™, and Enamine's source of drug-relevant chemical space through the REAL compounds, enabled very short and effective design-make-test-analyze cycles across its research infrastructure.

Enamine's profound knowledge of chemical space, namely with its REAL compounds, is the world's largest collection of make-on-demand small molecules that represents a significant fraction of such synthetically accessible chemical space. Its member molecules are REadily AccessibLe through validated parallel synthesis protocols using qualified in-stock building blocks.

Company Summaries:

EMUNO Therapeutics

EMUNO Therapeutics, a spin-off from the University Medical Centre Freiburg founded in 2024, develops new drugs to control immunity, treat diseases, and enhance human health and wellbeing. EMUNO designs and applies superior identification and optimization strategies tailored for each individual target to create therapeutics that promote or dampen specific immune responses. The company is run by a highly motivated team who combines in-depth experience in immunology, science, pharma and business. We are all passionate to improve patients' lives by controlling immunity. In 2025, EMUNO received a highly prestigious EIC Transition Grant from the European Innovation Council for the preclinical development of their drug candidate EMT-224.

For more information, please visit: www.emuno.com/

Enamine

Enamine is the leading provider of chemical compounds and a scientifically driven, integrated discovery Contract Research Organisation for integrated discovery with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery.

For more information, please visit: www.enamine.net/

Contact Information

EMUNO Therapeutics

Dr. Emilia Neuwirt

Co-founder & CEO

Email: emilia.neuwirt@emuno.com

Enamine

Oleksii Gavrylenko

Director of Marketing

Email: o.gavrylenko@enamine.net

Oleksii Gavrylenko

Enamine Ltd

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/884942549>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.